Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition
On the other hand, those in the placebo clinical trial group only showed average weight reductions of 3% [3]
Injection treatment resulted in significant improvements in all signs of nerve repair
When it occurs, it is more often linked to rapid weight loss or changes in nutrition rather than a direct effect of the medication itself
Secondary outcomes showed that while VAT decreased, subcutaneous adipose tissue (SAT) actually increased slightly in tesamorelin-treated patients (by ~3-8%), which is metabolically favorable as subcutaneous fat is less pathogenic than visceral fat
Nakamura H, Tanaka T, Zheng C, Afione SA, Warner BM, Noguchi M, et al